Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo. While the experimental medicine, ziltivekimab, did show some biological effect, it didn’t translate into a statistically meaningful reduction in MACE, defined as…
People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in Copenhagen, Denmark, March 26, 2026. Tom Little | Reuters Novo Nordisk hiked its annual profit guidance on Wednesday, as the drugmaker said its Wegovy weight-loss pill performed better than expected in the first three months of the…
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images Shares of Novo Nordisk rose more than 8% on Friday after early prescription data showed an encouraging start to the U.S. launch of the company’s new GLP-1 pill for obesity. In…
Still life of the big three injectable prescription weight loss medicines. Ozempic, Victoza and Wegovy. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) Ucg | Universal Images Group | Getty Images Novo Nordisk‘s shift from a market darling to a serious underperformer has set the stage for a transitional 2026 as the Danish drugmaker…
Novo Nordisk shares received a much-needed end of the year boost as the Wegovy maker became the first drugmaker to secure approval of a GLP-1 pill for weight loss, in what one analyst called a “redemption for the investors” after the stock’s worst year ever. The U.S. Food and Drug Administration’s approval of Novo Nordisk’s…
The Food and Drug Administration on Monday approved a pill version of Wegovy, Novo Nordisk’s blockbuster weight loss drug. The Wegovy pill, as it’s called, is first oral version of a GLP-1 drug that has been brought to market for weight loss. A second pill, from Eli Lilly, is also expected to be approved in…
The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025. Nichlas Pollier | Bloomberg | Getty Images Shares of Novo Nordisk on Monday fell as much 11% after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet its main goal. The trial tested whether semaglutide — the…
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images Shares of Novo Nordisk climbed almost 5% Monday after the company’s blockbuster Wegovy obesity drug received accelerated approval from the U.S. Food and Drug Administration to treat a serious liver disease. The company on Friday…
Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Wegovy-maker Novo Nordisk said Wednesday that it was doubling down on direct-to-consumer sales as it contends with copycat compounders and Washington’s demands for lower domestic drug prices. Chief Financial Officer Karsten Munk Knudsen…
